System for simultaneous tissue-specific and disease-specific regulation of therapeutic gene expression

Human Gene Therapy

Volumn 14, Issue 13, 2003, Pages 1255-1264

  Chyung, Yung H ^a   Peng, Peter D ^a   Kay, Mark A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; METALLOTHIONEIN; ZINC;

ARTICLE; GENE EXPRESSION REGULATION; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LACZ GENE; PROMOTER REGION; REGULATORY MECHANISM; REPORTER GENE; TISSUE SPECIFICITY; TRANSGENE;

EID: 0042383232     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303403767740795     Document Type: Article

References (59)

1. ACSADI, G., DICKSON, G., LOVE, D.R., JANI, A., WALSH, F.S., GURUSINGHE, A., WOLFF, J.A., and DAVIES K.E. (1991). Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs. Nature 352, 815-818.
2. BARKSDALE, S.K., and BAKER, C.C. (1995). The human immunodeficiency virus type I Rev protein and the Rev-responsive element counteract the effect of an inhibitory 5′ splice site in a 3′ untranslated region. Mol. Cell. Biol. 15, 2962-2971.
3. BARTON, M.D., DUNLOP, J.W., PSALTIS, G., KULIK, J., DEGENARRO, L., and KWAK, S.P. (2002). Modified GFAP promoter auto-regulates tet-activator expression for increased transactivation and reduced tTA-associated toxicity. Brain Res. Mol. Brain Res. 101, 71-81.
4. BRENCHLEY, P.E. (2001). Antagonising angiogenesis in rheumatoid arthritis. Ann. Rheum. Dis. 60, 71-74.
5. CASADO, E., GOMEZ-NAVARRO, J., YAMAMOTO, M., ADACHI, Y., COOLIDGE, C. J., ARAFAT, W.O., BARKER, S.D., WANG, M.H., MAHASRESHTI, P.J., HEMMINKI, A., GONZALEZ-BARON, M., BARNES, M.N., PUSTILNIK, T.B., SIEGAL, G.P., ALVAREZ, R.D., and CURIEL, D.T. (2001). Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications. Clin. Cancer Res. 7, 2496-2504.
6. CHEN, Z.Y., YANT, S.R., HE, C.Y., MEUSE, L., SHEN, S., and KAY, M.A. (2001). Linear DNAs concatemerize in vivo and result in sustained transgene expression in mouse liver. Mol. Ther. 3, 403-410.
7. CHEN, Z.Y., EHRHARDT, A., and KAY, M.A. (2003). Mini circle DNA vector devoid of bacterial DNA results in persistent and high-level transgene expression in vivo. Mol. Ther. (in press).
8. CHOATE, K.A., and KHAVARI, P.A. (1997). Direct cutaneous gene delivery in a human genetic skin disease. Hum. Gene Ther. 8, 1659-1665.
9. 1-antitrypsin gene. Cell 41, 531-540.
10. DACHS, G.U., PATTERSON, A.V., FIRTH, J.D., RATCLIFFE, P.J., TOWNSEND, K.M.S., STRATFORD, I.J., and HARRIS, A.L. (1997). Targeting gene expression to hypoxic tumor cells. Nat. Med. 3, 515-520.
11. EHRHARDT, A., PENG, P.D., MEUSE, L., and KAY, M.A. (2003). Optimization of cis-acting elements for gene expression from non-viral vectors in vitro. Hum. Gene Ther. 14, 215-225.
12. FURTH, P.A., ONGE, L.S., BOGER, H., GRUSS, P., GOSSEN, M., KISTNER, A., BUJARD, H., and HENNIGHAUSEN, L. (1994). Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter. Proc. Natl. Acad. Sci. U.S.A. 91, 9302-9306.
13. GHERSA, P., GOBERT, R.P., SATTONNET-ROCHE, P., RICHARDS, C.A., MERLO PICH, E., and HOOFT VAN HUIJSDUIJNEN, R. (1998). Highly controlled gene expression using combinations of a tissue-specific promoter, recombinant adenovirus and a tetracycline-regulatable transcription factor. Gene Ther. 5, 1213-1220.
14. GILL, D.R., SMYTH, S.E., GODDARD, C.A., PRINGLE, I.A., HIGGINS, C.F., COLLEDGE, W.H., and HYDE S.C. (2001). Increased persistence of lung gene expression using plasmids containing the ubiquitin C or elongation factor 1 α promoter. Gene Ther. 8, 1539-1546.
15. GREENBERG, D., MIAO, C.H., HO, W.T., CHUNG, D.W., and DAVIE, E.W. (1995). Liver-specific expression of the human factor VII gene. Proc. Natl. Acad. Sci. U.S.A. 92, 12347-12351.
16. GU, J., ANDREEFF, M., ROTH, J.A., and FANG, B. (2002). hTERT promoter induces tumor-specific bax gene expression and cell killing in syngeneic mouse tumor model and prevents systemic toxicity. Gene Ther. 9, 30-37.
17. GUNDERSON, S.I., POLYCARPOU-SCHWARZ, M., and MATTAJ, I.W. (1998). U1 snRNP inhibits pre-mRNA polyadenylation through a direct interaction between U1 70K and poly(A) polymerase. Mol. Cell 1, 255-264.
18. HAHNE, M., RIMOLDI, D., SCHRÖTER, M., ROMERO, P., SCHREIER, M., FRENCH, L.E., SCHNEIDER, P., BORNAND, T., FONTANA, A., LIENARD, D., CEROTTINI, J.-C., and TSCHOPP, J. (1996). Melanoma cell expression of Fas (Apo-1/CD95) ligand: Implications for tumor escape. Science 274, 1363-1366.
19. HARVEY, B., KORUS, M., and GOLDMAN, E. (1999). The T7 concatemer junction sequence interferes with expression from a downstream T7 promoter in vivo. Gene Expr. 8, 141-149.
20. HERNANDEZ-ALCOCEBA, R., PIHALJA, M., NUNEZ, G., and CLARKE, M.F. (2001). Evaluation of a new dual-specificity promoter for selective induction of apoptosis in breast cancer cells. Cancer Gene Ther. 8, 298-307.
21. HOESS, R.H., ZIESE, M., and STERNBERG, N. (1982). P1 site-specific recombination: Nucleotide sequence of the recombining sites. Proc. Natl. Acad. Sci. U.S.A. 79, 3398-3402.
22. HOESS, R., WIERZBICKI, A., and ABREMSKI, K. (1985). Formation of small circular DNA molecules via an in vitro site-specific recombination system. Gene 40, 325-329.
23. IDO, A., UTO, H., MORIUCHI, A., NAGATA, K., ONAGA, Y., ONAGA, M., HORI, T., HIRONO, S., HAYASHI, K., TAMAOKI, T., and TSUBOUCHI, H. (2001). Gene therapy targeting for hepatocellular carcinoma: Selective and enhanced suicide gene expression regulated by a hypoxia-inducible enhancer linked to a human α-feto-protein promoter. Cancer Res. 61, 3016-3021.
24. ISNER, J.M. (2002). Myocardial gene therapy. Nature 415, 234-239.
25. JEROME, V., and MULLER, R. (1998). Tissue-specific, cell cycle-regulated chimeric transcription factors for the targeting of gene expression to tumor cells. Hum. Gene Ther. 9, 2653-2659.
26. KACZMARCZYK, S.J., and GREEN, J.E. (2001). A single vector containing modified cre recombinase and LOX recombination sequences for inducible tissue-specific amplification of gene expression. Nucleic Acids Res. 29, E56.
27. KELLENDONK, C., TRONCHE, F., CASANOVA, E., ANLAG, K., OPHERK, C., and SCHUTZ, G. (1999). Inducible site-specific recombination in the brain. J. Mol. Biol. 285, 175-182.
28. KERBEL, R.S. (2000). Tumor angiogenesis: Past, present and the near future. Carcinogenesis 21, 505-515.
29. KOGA, S., HIROHATA, S., KONDO, Y., KOMATA, T., TAKAKURA, M., INOUE, M., KYO, S., and KONDO, S. (2001). FADD gene therapy using the human telomerase catalytic subunit (hTERT) gene promoter to restrict induction of apoptosis to tumors in vitro and in vivo. Anticancer Res. 21, 1937-1943.
30. KOSHIKAWA, N., TAKENAGA, K., TAGAWA, M., and SAKIYAMA, S. (2000). Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells. Cancer Res. 60, 2936-2941.
31. KRAMER, M.G., BARAJAS, M., RAZQUIN, N., BERRAONDO, P., RODRIGO, M., WU, C., QIAN, C., FORTES, P., and PRIETO, J. (2003). In vitro and in vivo comparative study of chimeric liver-specific promoters. Mol. Ther. 7, 375-385.
32. LEE, R.J., SPRINGER, M.L., HORTELANO, G., BOULEY, D.M., WONG, J., KRAFT, P.E., and BLAU, H.M. (2000). VEGF gene delivery to myocardium: Deleterious effects of unregulated expression. Circulation 102, 898-901.
33. LEE, S., PARK, U., and LEE, Y.L. (2001). Hepatitis C virus core protein transactivates insulin-like growth factor II gene transcription through acting concurrently on Egr1 and Sp1 sites. Virology 283, 167-177.
34. LIEBER, A., HIE, C.Y., KIRILLOVA, I., and KAY, M.A. (1996). Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo. J. Virol. 70, 8944-8960.
35. LOONSTRA, A., VOOIJS, M., BEVERLOO, H.B., ALLAK, B.A., VAN DRUNEN, E., KANAAR, R., BERNS, A., and JONKERS, J. (2001). Growth inhibition and DNA damage induced by Cre recombinase in mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 98, 9209-9214.
36. LOSORDO, D.W., VALE, P.R., SYMES, J.F., DUNNINGTON, C.H., ESAKOF, D.D., MAYSKY, M., ASHARE, A.B., LATHI, K., and ISNER, J.M. (1998). Gene therapy for myocardial angiogenesis: Initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 98, 2800-2804.
37. MCCORMICK, F. (2001). Cancer gene therapy: Fringe or cutting edge? Nat. Rev. Cancer 1, 130-141.
38. MENG SOO, H., GARZINO-DEMO, A., HONG, W., TAN, Y.H., TAN, Y.J., GOH, P.-Y., LIM, S.G., and LIM, S.P. (2002). Expression of a full-length hepatitis C virus cDNA upregulates the expression of CC chemokines MCP-1 and RANTES. Virology 303, 253-277.
39. MIZUGUCHI, H., and KAY, M.A. (1999). A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors. Hum. Gene Ther. 10, 2013-2017.
40. MODLICH, U., PUGH, C.W., and BICKNELL, R. (2000). Increasing endothelial cell specific expression by the use of heterologous hypoxic and cytokine-inducible enhancers. Gene Ther. 7, 896-902.
41. NAKAI, H., STORM, T.A., and KAY, M.A. (2000). Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors. Nat. Biotechnol. 18, 527-532.
42. NETTELBECK, D.M., JEROME, V., and MULLER, R. (1999). A dual specificity promoter system combining cell cycle-regulated and tissue-specific transcriptional control. Gene Ther. 6, 1276-1281.
43. NETTELBECK, D.M., JEROME, V., and MULLER, R. (2000). Gene therapy: Designer promoters for tumour targeting. Trends Genet. 16, 174-181.
44. PHILLIPS, M.I., TANG, Y., SCHMIDT-OTT, K., QIAN, K., and KAGIYAMA, S. (2002). Vigilant vector: Heart-specific promoter in an adeno-associated virus vector for cardioprotection. Hypertension 39, 651-655.
45. PLUMB, J.A., BILSLAND, A., KAKANI, R., ZHAO, J., GLASSPOOL, R.M., KNOX, R.J., EVANS, T.R., and KEITH, W.N. (2001). Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954. Oncogene 20, 7797-7803.
46. POLYAK, S.J., KHABAR, K.S.A., PASCHAL, D.M., EZELLE, H.J., DUVERLIE, G., BARBER, G.N., LEVY, D.E., MUKAIDA, N., and GRETCH, D.R. (2001). Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J. Virol. 75, 6096-6106.
47. PRENTICE, H., BISHOPRIC, N.H., HICKS, M.N., DISCHER, D.J., WU, X., WYLIE, A.A., and WEBSTER, K.A. (1997). Regulated expression of a foreign gene targeted to the ischaemic myocardium. Cardiovasc. Res. 35, 567-574.
48. RAY, R.B., LAGGING, L.M., MEYER, K., STEELE, R., and RAY, R. (1995). Transcriptional regulation of cellular and viral promoters by the hepatitis C virus core protein. Virus Res. 37, 209-220.
49. SCHWARTZ, B., BENOIST, C., ABDALLAH, B., RANGARA, R., HASSAN, A., SCHERMAN, D., and DEMENEIX, B.A. (1996). Gene transfer by naked DNA into adult mouse brain. Gene Ther. 3, 405-411.
50. SCHWARZ, E.R., SPEAKMAN, M.T., PATTERSON, M., HALE, S.S., ISNER, J.M., KEDES, L.H., and KLONER, R.A. (2000). Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat: Angiogenesis and angioma formation. J. Am. Coll. Cardiol. 35, 1323-1330.
51. SHIBATA, T., GIACCIA, A.J., and BROWN, J.M. (2000). Development of a hypoxia-responsive vector for tumor-specific gene therapy. Gene Ther. 7, 493-498.
52. SOHAL, D.S., NGHIEM, M., CRACKOWER, M.A., WITT, S.A., KIMBALL, T.R., TYMITZ, K.M., PENNINGER, J.M., and MOLKENTIN, J.D. (2001). Temporally regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein. Circ. Res. 89, 20-25.
53. SPRANGER, J., and PFEIFFER, A.F. (2001). New concepts in pathogenesis and treatment of diabetic retinopathy. Exp. Clin. Endocrinol. Diabetes 109, S438-S450.
54. STERNBERG, N., and HAMILTON, D. (1981). Bacteriophage P1 site-specific recombination. I. Recombination between loxP sites. J. Mol. Biol. 150, 467-486.
55. STERNBERG, N., HAMILTON, D., and HOESS, R. (1981). Bacteriophage P1 site-specific recombination. II. Recombination between loxP and the bacterial chromosome. J. Mol. Biol. 150, 487-507.
56. STUART, G.W., SEARLE, P.F., CHEN, H.Y., BRINSTER, R.L., and PALMITER, R.D. (1984). A 12-base-pair DNA motif that is repeated several times in metallothionein gene promoters confers metal regulation to a heterologous gene. Proc. Natl. Acad. Sci. U.S.A. 81, 7318-7322.
57. THYAGARAJAN, B., GUIMARAES, M.J., GROTH, A.C., and CALOS, M.P. (2000). Mammalian genomes contain active recombinase recognition sites. Gene 244, 47-54.
58. WESSELING, J.G., YAMAMOTO, M., ADACHI, Y., BOSMA, P.J., VAN WIJLAND, M., BLACKWELL, J.L., LI, H., REYNOLDS, P.N., DMITRIEV, I., VICKERS, S.M., HUIBREGTSE, K., and CURIEL, D.T. (2001). Midkine and cyclooxygenase-2 promoters are promising for adenoviral vector gene delivery of pancreatic carcinoma. Cancer Gene Ther. 8, 990-996.
59. YAMAMOTO, M., ALEMANY, R., ADACHI, Y, GRIZZLE, W.E., and CURIEL, D.T. (2001). Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers. Mol. Ther. 3, 385-394.